Navigation Links
bioLytical recognized by Premier as Breakthrough Technology Award Winner for INSTI HIV Rapid Point of Care Test
Date:1/10/2017

RICHMOND, BC, Jan. 10, 2017 /PRNewswire/ - bioLytical Laboratories, a world leader in rapid infectious disease tests, today announced receipt of the prestigious Breakthrough Technology Award from Premier Inc. for its INSTI® HIV-1/HIV-2 rapid point of care diagnostic test.  Premier is a healthcare improvement company that unites an alliance of approximately 3,750 hospitals and 130,000 other provider organizations to whom the INSTI HIV test will now been made available at negotiated pricing and terms.

"We are very pleased and proud to receive this award from Premier, and to offer Premier's members and their healthcare professionals the benefits of our INSTI HIV-1/HIV-2 rapid point of care diagnostic test," said Livleen Veslemes, bioLytical's Chief Operating Officer and Chief Financial Officer. "This offering further demonstrates our commitment to improve patient care in the United States and support the CDC guidelines which recommend HIV screening be a part of routine clinical care in all health-care settings."

Clinicians and other health care system members of Premier selected the innovative INSTI® HIV-1/HIV-2 rapid point of care diagnostic test based on the product's unique properties and the potential to improve patient care with more routine HIV screening.

bioLytical's INSTI HIV-1/HIV-2 Rapid Antibody Test is a rapid in vitro qualitative test for the detection of antibodies to Human Immunodeficiency Virus Type 1 and Type 2 in human whole blood, fingerstick blood, or plasma. The test is intended for use by trained personnel in a variety of settings such as hospitals, clinical laboratories, and physician offices as a screening assay capable of providing test results in as little as 60 seconds. The INSTI test kit has a unique immunofiltration "flow-through" design which leads to accelerated and accurate results.  

About bioLytical Laboratories Inc.

bioLytical Laboratories Inc. is a privately owned Canadian company engaged in the research, development and commercialization of rapid, point of care in vitro medical diagnostics using its proprietary INSTI technology platform.  With a world-wide footprint of regulatory approvals including US FDA approval, Health Canada approval and CE mark, bioLytical markets and sells its INSTI HIV test globally and INSTI HIV/Syphilis Multiplex test in Europe.  The INSTI product line provides highly accurate test results in 60 seconds or less, far faster than the 15-20 minutes required for competitors' tests based on lateral flow technology.  bioLytical has an active R&D program with a pipeline that includes tests for diseases such as Zika, Dengue, Chikungunya, Hepatitis C and Ebola, among others.  The company also provides contract services to adapt the INSTI platform to meet custom functional and technical diagnostic testing requirements.  For more information, please visit www.biolytical.com.


'/>"/>
SOURCE bioLytical Laboratories
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. bioLytical Introduces INSTI HIV Self Test to Kenyan Regulated Pharmacy Network
2. bioLyticals INSTI HIV Test Detects gp41 specific IgM Antibodies
3. bioLytical to Present Findings of Early HIV Detection
4. bioLytical Partners with Walgreens and Donates HIV Tests for National HIV Testing Day
5. bioLytical Laboratories Grants Exclusive Global License for 60 Second Ebola Assay
6. bioLyticals INSTI HIV Assay Receives FDA Approval for HIV-2
7. Equicare Health recognized in 2016 Global Digital Health 100 as one of the top innovative digital companies by The Journal of mHealth
8. CereScan Recognized as One of Angel Capital Summit’s Most Promising Companies
9. AllegroGraph Recognized by Corporate America Magazine as Best in Semantic Web Technology - USA & Leader in Graph Database Products
10. AllegroGraph Recognized Among Top 10 Analytics Solution Providers by Pharma Tech Outlook
11. SFI International Recognized for Adopting Bacopa through American Botanical Councils Adopt-an-Herb Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... A new study published ... frozen and fresh in vitro fertilization (IVF) transfer cycles. The multi-center ... success. , After comparing the results from the fresh and frozen transfer cohorts, ...
(Date:10/10/2017)... ... , ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. ... The event entitled “Stem Cells and Their Regenerative Powers,” was held on August ... MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic ...
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings announced ... by which its ProCell stem cell therapy prevents ... ischemia.  The Company, demonstrated that treatment with ProCell ... limbs saved as compared to standard bone marrow ... HGF resulted in reduction of therapeutic effect.  ...
(Date:10/7/2017)... (PRWEB) , ... October 06, ... ... years’ experience providing advanced instruments and applications consulting for microscopy and surface ... expertise in application consulting, Nanoscience Analytical offers a broad range of contract ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by ... Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to ... USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 30.37% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
Breaking Biology News(10 mins):